LogicBio Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2017 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
LogicBio Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2017 to Q3 2022.
  • LogicBio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2022 was -$5.78M, a 43.3% increase year-over-year.
  • LogicBio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2022 was -$26.5M, a 29.9% increase year-over-year.
  • LogicBio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$40M, a 22.7% decline from 2020.
  • LogicBio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$32.6M, a 18.7% increase from 2019.
  • LogicBio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2019 was -$40.1M, a 128% decline from 2018.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$26.5M -$5.78M +$4.41M +43.3% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$31M -$5.04M +$5.46M +52% Apr 1, 2022 Jun 30, 2022 10-Q 2022-11-14
Q1 2022 -$36.4M -$6.66M +$3.62M +35.2% Jan 1, 2022 Mar 31, 2022 10-Q 2022-11-14
Q4 2021 -$40M -$9.06M -$2.16M -31.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-04
Q3 2021 -$37.9M -$10.2M -$2.15M -26.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$35.7M -$10.5M -$2.27M -27.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$33.4M -$10.3M -$827K -8.75% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$32.6M -$6.9M +$4.57M +39.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-04
Q3 2020 -$37.2M -$8.04M +$2.88M +26.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$40.1M -$8.23M +$1.82M +18.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$41.9M -$9.46M -$1.76M -22.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$40.1M -$11.5M -$4.4M -62.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-15
Q3 2019 -$35.7M -$10.9M -$6.25M -134% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$29.5M -$10M -$6.46M -180% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$23M -$7.7M -$5.39M -234% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$17.6M -$7.06M Oct 1, 2018 Dec 31, 2018 10-Q 2020-05-11
Q3 2018 -$4.67M -$3.63M -347% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$3.59M Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$2.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q3 2017 -$1.04M Jul 1, 2017 Sep 30, 2017 10-Q 2018-12-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.